INTRODUCTION
Almost to the century after the initial clinical description of childhood spinal muscular atrophy (SMA) (Werdnig, 1891) a new era of investigation into the nature of SMA was inaugurated when Conrad Gilliam and his group at Columbia University established genetic linkage for this autosomal recessive disorder to chromosome 5q (Brzustowicz et al., 1990) . In 6 years the pace of research has accelerated markedly: an extensive international effort to identify the gene is documented in over 50 papers by 240 authors at a dozen centers. One early by-product of this search was the discovery that the SMA-critical region of chromosome 5q is unusually unstable and that this genetic instability is likely responsible for the high incidence and worldwide distribution of SMA (Carpten et al., 1994; Theodosiou et al., 1994; Thompson et al., 1995; Crawford, 1996) . By early 1995, the search had narrowed sufficiently for two neighboring but unrelated candidate genes to be proposed for the disorder (Lefebvre et al., 1995; Roy et al., 1995a) . The arguments buttressing the candidacy of each of these two genes contrast strong biologic plausibility against high genetic probability. The plausible candidate gene, neuronal apoptosis inhibitory protein (NAIP), has displayed anti-apoptotic function-an activity that matches closely a standing hypothesis that SMA is a disorder of development. The probable candidate gene, survival motor neuron (SMN), is deleted in over 95% of patients with SMA and disabling point mutations have been found in a number of the remaining patients where they were pursued.
Investigations into the pathogenesis of SMA are now turning to the cellular biology of NAIP and SMN and to the generation of gene-targeted animal models. Meanwhile, available animal models of motor neuron degeneration raise new questions about the multiple pathways of selective motor neuron vulnerability. New clinical insights and findings also raise some unexpected questions. The current vigor of SMA research stands as an outstanding illustration of how insight from multiple levels-from epidemiology, clinical trials, and individual patient investigations to pathology, biochemistry, classic genetics, and now molecular genetics and cell biology-contribute to and draw strength from one another.
EPIDEMIOLOGY AND NOSOLOGY
SMA, an autosomal recessive disease, is the most frequent monogenic cause of death in infancy and a major cause of childhood morbidity due to weakness. It is common in all areas of the world where incidence has been studied (Emery, 1991) . In Europe and North America, the best estimates are that 1 in 16,000 to 25,000 infants dies of the severe infantile form, while an approximately equal number have a milder form. The disease exists as a spectrum, usually arbitrarily divided by clinical criteria into several groups. Infants with the severe form (known variously as WerdnigHoffmann disease, severe infantile SMA, or SMA type 1) generally manifest weakness before 3 months and certainly before 6 months and are so profoundly weak that they are never able to maintain a sitting posture. In this group, average life expectancy is 8 months, with 75 and 95% mortality by the first and second birthdays (Ignatius, 1994; Thomas & Dubowitz, 1994) . Children with milder forms of SMA (also known as SMA type 2,
